Bridging ELISA for Anti-Drug Antibody Detection with Oligomeric IgG
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-drug antibody (ADA) detection assays face challenges in high drug tolerance and interference from rheumatoid factors, leading to false positive results, especially in serum samples from patients with autoimmune diseases like rheumatoid arthritis.
Innovation Solution
A bridging enzyme-linked immunosorbent assay (ELISA) with increased drug tolerance and reduced false positives, achieved through synergistic interactions of higher biotinylated and digoxigenylated reagent concentrations, simultaneous incubation, prolonged incubation time, use of mono-coupled reagents, and addition of oligomeric human IgG to suppress interference from rheumatoid factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADA ELISA is used, then the assay can detect anti-drug antibodies, but the drug tolerance is low and false positive results occur due to interference from rheumatoid factors
Solution Approach 1:
The patent introduces an excess of free drug as an intermediary substance that competes with the therapeutic antibody for binding to anti-drug antibodies. This competitive binding mechanism allows the assay to specifically detect true ADA while preventing false positive signals from rheumatoid factors, as the free drug selectively occupies ADA binding sites without interfering with RF detection
Solution Approach 2:
The patent optimizes multiple assay parameters including incubation time (extended to 16-24 hours), reagent concentrations (biotinylated and digoxigenylated reagents at 0.5-10 μg/ml), and serum matrix content (7.5% or more). These parameter changes collectively enhance drug tolerance by 10-fold while maintaining assay sensitivity and reducing false positives from rheumatoid factor interference
2Reliability
If the concentration of capture and tracer reagents is increased, then the drug tolerance of the assay is improved, but the complexity of the assay increases
Solution Approach 1:
The patent combines multiple reagents (capture antibody, tracer antibody, biotinylated reagent, digoxigenylated reagent, and serum matrix) into a single simultaneous incubation step. This merging of reagents and steps simplifies the overall procedure while achieving the required 10-fold increase in drug tolerance through synergistic interactions among the combined components
3Measurement precision
If simultaneous incubation of serum sample with capture and tracer reagents is performed, then the assay sensitivity and drug tolerance are improved, but the incubation time is prolonged
Solution Approach 1:
The patent implements continuous incubation of the serum sample with all capture and tracer reagents simultaneously present throughout the 16-24 hour period. This continuous interaction allows anti-drug antibodies to bind to both capture and tracer reagents concurrently, maximizing signal generation and sensitivity while the extended time ensures equilibrium is reached for accurate detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay demonstrates at least 10-fold higher drug tolerance and significantly reduces false positive results, effectively detecting anti-drug antibodies in serum samples with high therapeutic antibody concentrations and minimizing interference from rheumatoid factors.
Implementation Method 1
a capture drug antibody and a tracer drug antibody are used in an enzyme linked immunosorbent assay for the detection of anti-drug antibodies
Implementation Method 2
enzyme-linked immunosorbent assay (ELISA) for the detection of anti-drug antibodies
Data Source
AI summary
Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 μg/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.